{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030276","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.714879+00:00","generated_at":"2026-05-31T00:59:58.773481+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxart initiates sentinel cohort of Phase 2b oral COVID-19 vaccine trial; BARDA raises funding to $456M","bullets":["Modification No. 3 increased total estimated ceiling to ~$456.1M (+$3.2M) and allotted funding to ~$96.5M (+$30.8M).","Sentinel cohort of 400 participants (200 Vaxart oral pill, 200 mRNA comparator) begins; 30-day safety data will trigger enrollment of 10,000.","Trial will measure efficacy against symptomatic/asymptomatic disease, systemic and mucosal immunity, and safety.","Funding via Project NextGen (BARDA); full Phase 2b primary efficacy analysis at 12 months post-vaccination.","Vaxart's XBB vaccine construct and newly funded KP.2-targeting construct are part of the study."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030276","json":"https://secwatch.observer/filing/0001437749-24-030276.json","markdown":"https://secwatch.observer/filing/0001437749-24-030276.md","text":"https://secwatch.observer/filing/0001437749-24-030276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774924030276/0001437749-24-030276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774924030276/vxrt20240930_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:59:58.773481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}